Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47.

The 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.

Bringing together the leading experts, we will explore the clinical development of CD47 checkpoint blockades, combination strategies, macrophage repolarization approaches and engineered macrophages.

Join the trailblazers of macrophage therapeutic development, from the likes of Carisma Therapeutics, Faron Pharmaceuticals, and Verseau Therapeutic, as we come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.